ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Article
- IL-1β-Triggered Long Non-coding RNA CHRF Induces Non-Small Cell Lung Cancer by Modulating the microRNA-489/Myd88 Axis.Journal of Cancer · 2022Article
- Review
- miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2.Oncology letters · 2020Article
- Effects of miR-489 targeting on SOX4 gene on proliferation and apoptosis of human hepatocellular carcinoma cells.African health sciences · 2020Article
- LncRNA SNHG5 regulates SOX4 expression through competitive binding to miR-489-3p in acute myeloid leukemia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- miR-489-3p/SIX1 Axis Regulates Melanoma Proliferation and Glycolytic Potential.Molecular therapy oncolytics · 2020Article
- MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1.Experimental and therapeutic medicine · 2020Article
- MicroRNA in Lung Cancer Metastasis.Cancers · 2019Review
- Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer.Molecular cancer research : MCR · 2018Article
- MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Article
- Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP.Oncotarget · 2017Article
- MicroRNA‑21 increases cell viability and suppresses cellular apoptosis in non‑small cell lung cancer by regulating the PI3K/Akt signaling pathway.Molecular medicine reports · 2017Article
- Review
- LncRNA CHRF-induced miR-489 loss promotes metastasis of colorectal cancer via TWIST1/EMT signaling pathway.Oncotarget · 2017Article
- Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer.Oncotarget · 2017Review
- microRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7.Translational oncology · 2017Article
- Article
- miR-489 Suppresses Proliferation and Invasion of Human Bladder Cancer Cells.Oncology research · 2016Article
- miR-489 inhibits silica-induced pulmonary fibrosis by targeting MyD88 and Smad3 and is negatively regulated by lncRNA CHRF.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNAs are small, non-coding RNAs that contribute into various biological processes during cancer progression. However, the potential role of miR-489 in the development of Non-Small Cell Lung Cancer (NSCLC) is not demonstrated. In present study, miR-489 was down-regulated both in tumor tissues and cells. Inhibition of miR-489 promoted cells invasion by using an invasion assay. Furthermore, miR-489 could regulate SUZ12 as shown by luciferase reporter and Western blot assays. Aberrant miR-489 expression could regulate the molecular changes (E-cadherin, N-cadherin, and Vimentin) of epithelial mesenchymal transition (EMT). In conclusion, our study revealed that miR-489 may play an essential role in the progression of NSCLC.
Indexed as
Identifiers
25833694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.